Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: Part 1 results Meeting Abstract
| Authors: | Friedman, C.; Carvajal, R.; Davar, D.; Castanon, E.; Ascierto, P.; Calvo, E.; O'Hara, M.; Powell, S.; Shapira-Frommer, R.; Garralda, E.; Renouf, D. J.; Perets, R.; Yunan, M.; Ravindran, P.; Hammell, A.; O'Brien, S.; Xu, K.; Wilson, N.; Jhatakia, A.; Mukhopadhyay, A.; Gutierrez, M. |
| Abstract Title: | Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: Part 1 results |
| Meeting Title: | 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 10 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Nov 8-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-11-01 |
| Start Page: | A620 |
| End Page: | A621 |
| Language: | English |
| ACCESSION: | WOS:000919423400554 |
| DOI: | 10.1136/jitc-2022-SITC2022.0592 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 592 -- Source: Wos |
